

Special Issue

Application of Human Three-Dimensional Multicellular Models for Personalized Cancer Therapy

Message from the Guest Editor

Personalized cancer therapy based on individual tumor characteristics is playing an increasingly important role in cancer treatment. Currently, personalized oncology is mainly defined as the molecular profiling of tumors to select a targeted therapy for the individual cancer patient. However, a significant number of cancer patients do not benefit from this treatment selection strategy. This highlights the need to consider additional tumor characteristics relevant to drug response and to incorporate additional testing systems beyond the evaluation of genetic information into the treatment decision process. The Special Issue "Application of Three-Dimensional Human Multicellular Models for Personalized Cancer Therapy" aims to provide an update on complex 3D human cancer models such as organoids, spheroids, tissue cultures, on-a-chip platforms, bioprinted models, and microfluidic systems developed for drug selection for individual cancer patients.

Guest Editor

Dr. Barbara Mayer

Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, H02-312, Marchioninistrasse 15, 81377 Munich, Germany

Deadline for manuscript submissions

closed (31 December 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/170030

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)